Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial

Transplantation

Volumn 93, Issue 1, 2012, Pages 61-68

  Witzke, Oliver ^a   Hauser, Ingeborg A ^b   Bartels, Michael ^c   Wolf, Gunter ^d   Wolters, Heiner ^e   Nitschke, Martin ^f  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cytomegalovirus; Kidney transplantation; Prophylaxis; Valganciclovir

Indexed keywords

VALGANCICLOVIR; VIRUS DNA;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; AUSTRIA; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84655163830     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318238dab3     Document Type: Article

References (25)

1. Weir MR. Medical management of kidney transplantation. Cytomegalovirus in renal transplantation. Philadelphia, PA: Lippincott Williams & Wilkins 2005:Chapter 28.
2. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
4. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
5. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550.
6. Sharples LD, Jackson CH, Parameshwar J, et al. Diagnostic accuracy of coronary angiography and risk factors for postheart-transplant cardiac allograft vasculopathy. Transplantation 2003; 76: 679.
7. Fateh-Moghadam S, Bocksch W, Wessely R, et al. Cytomegalovirus infection status predicts progression of heart transplant vasculopathy. Transplantation 2003; 76: 1470.
8. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
9. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
10. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
11. AST (American Society of Transplantation). Cytomegalovirus. Am J Transplant 2004; 4: 51.
12. Sun H-Y, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008; 8: 2111.
13. Kliem V, Radermacher J, Burg M, et al. CMV Ganciclovir prophylaxis improves long-term graft survival for sero-positive (D+/R+) renal graft recipients. American Transplant Congress 2010; Abstract Number: 250644.
14. Reischig T. Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 2010; 8: 903.
15. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
16. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645.
17. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantationchallenging the status quo. Clin Transplant 2007; 21: 149.
18. Wittke S, Haubitz M, Walden M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005; 5: 2479.
19. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340.
20. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol 2006; 7: 230.
21. Pellegrin I, Garrigue I, Binquet C, et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999; 37: 3124.
22. Von Muller L, Hampl W, Hinz J, et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 2285.
23. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
25. Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65: 2426.